

K-Clinical Skincare: CISL Seoul Leads the Shift Toward Dermatology-Grade Efficacy in Consumer Beauty

SEOUL, SEOUL, SOUTH KOREA,
October 10, 2025 /EINPresswire.com/ -As demand for performance-driven
skincare rises globally, <u>CISL Seoul</u> today
announced the launch of its <u>K-Clinical</u>
<u>Skincare</u> line, a new category
combining dermatological science with
at-home accessibility. The line is
designed to deliver results comparable
to in-clinic treatments through
advanced formulation and ingredient
precision.

Defining "K-Clinical" Skincare
While K-Beauty has long emphasized
hydration and radiance, CISL Seoul's KClinical concept focuses on measurable
outcomes backed by dermatology. The
line applies medical-grade

PDRN RETINOL
ASIOCAL

SINGLE STATE OF THE STATE OF THE

CISL Seoul's K-Clinical skincare line, including the Dual Infushot™ Skinbooster Serum, BioBarrier™ Recovery Capsule Cream, and Ultra Wrinkle Correxion™ Serum — dermatologist-developed formulations bringing clinical efficacy home.

principles—such as regenerative actives and stability-controlled formulations—to daily skincare routines.

Founder's Vision



K-Clinical represents the next evolution, science, transparency, and trust."

Alex Lee, CEO of CISL Seoul

CISL Seoul was established by Alex Lee, a long-term dermatology patient who partnered with Seoul-based dermatologists to address the gap between clinical procedures and over-the-counter products.

"Our goal was to take what works inside the clinic and make it safe and effective for everyday use," said Lee. "K-

Clinical represents that balance between scientific rigor and accessibility."

Product Line Overview

The K-Clinical line integrates medical-grade ingredients such as PDRN (Polydeoxyribonucleotide), known for its regenerative properties.

Key products include:

- Dual Infushot™ Skinbooster Serum, featuring a dual-chamber design that keeps actives separate until application.
- BioBarrier™ Recovery Capsule Cream, formulated to strengthen and repair the skin barrier.
- Ultra Wrinkle Correxion™ Serum, targeting visible signs of aging through firming and elasticity support.

Industry Context

According to The Insight Partners, the global skincare and cosmetics market is projected to reach USD 213 billion by 2028, with the cosmeceuticals sector surpassing USD 120 billion. The emergence of clinical-grade formulations for home use highlights a broader shift toward efficacy and transparency in consumer skincare.

About CISL Seoul

Founded in Seoul, South Korea, CISL Seoul develops K-Clinical skincare inspired by dermatological science. The brand's mission is to provide clinic-level efficacy through daily skincare routines, uniting Seoul's medical innovation with global consumer needs.

Learn more at <u>www.cislseoul.com</u>

Nuria

CISL Seoul +82 10-7245-9335

email us here

Visit us on social media:

Instagram

This press release can be viewed online at: https://www.einpresswire.com/article/856981147

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.